Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Gene Points to Aggressive Gleason 7 Prostate Cancer

December 31st 2014

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

Optimal Rituximab Dose in Lymphoma

December 24th 2014

Rituximab dose should be based on age and sex.

Trials Show Efficacy of PARP-Targeted Agent in Prostate Cancer

December 22nd 2014

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

HCI Connects Precision Medicine With Patient-Centered Care

December 19th 2014

Latest News & Insight: December 19, 2014

December 19th 2014

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Research and Policy Paradigms Must Consider Patients' Assessments of Relevant Goals and Outcomes

December 2nd 2014

What patients with cancer perceive as relevant clinical outcomes, and how these outcomes are assessed, is important in the provision of routine care and in the arena of clinical trials.

From Bedside to Bench

November 29th 2014

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

PARP Inhibitors for Breast and Ovarian Cancers

November 26th 2014

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.

Challenges for the Future of Gynecologic Cancers

November 26th 2014

Emerging Therapies in Cervical Cancer

November 26th 2014

Bevacizumab in Recurrent Metastatic Cervical Cancer

November 26th 2014

Cervical Cancer Screening and Prevention

November 26th 2014

Promising Treatments in Ovarian Cancer

November 26th 2014

Bevacizumab in Ovarian Cancer

November 26th 2014

Platinum Resistance in Ovarian Cancer

November 26th 2014

CA-125 Testing in Ovarian Cancer

November 26th 2014

Intraperitoneal Chemotherapy in Ovarian Cancer

November 26th 2014

Antiangiogenic Agents in Ovarian Cancer

November 26th 2014

Treatment Options in Ovarian Cancer

November 26th 2014